Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02586987 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT02586987 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 58 participants.
The verdict
NCT02586987, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
This is a Phase I, open-label, multi-centre, drug combination study of double and triple combination oral selumetinib (AZD6244 Hyd-sulfate) plus intravenous (IV) MEDI4736 and oral selumetinib plus IV MEDI4736 and IV tremelimumab in patients with advanced solid tumours.
Interventions
- DRUG Tremelimumab
- DRUG Selumetinib
- DRUG MEDI4736
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2015-12-28 |
| Est. Completion | 2019-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02586987
The ClinicalTrials.gov registry entry for NCT02586987 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tremelimumab is the first listed.
NCT02586987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02586987 about?
NCT02586987 is a clinical study titled "A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours". This is a Phase I, open-label, multi-centre, drug combination study of double and triple combination oral selumetinib (AZD6244 Hyd-sulfate) plus intravenous (IV) MEDI4736 and oral selumetinib plus IV MEDI4736 and IV tremelimumab in patients with advanced solid tumours.
What is the current status of trial NCT02586987?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2015-12-28. Estimated completion is 2019-09-20.
What interventions are being tested in trial NCT02586987?
The interventions under investigation include: Tremelimumab (DRUG), Selumetinib (DRUG), MEDI4736 (DRUG).
Who is sponsoring clinical trial NCT02586987?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.